Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.67 |
| ▸ | PARP1 | P09874 | 8/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.59 |
| ▸ | PARP14 | Q460N5 | 12/20 | 0.57 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648663 | 0.92 | PARP1 (0.70) | PDE10APARP1PARP2PARP14 | |
| SCHEMBL6647065 | 0.88 | PDE10A (0.59) | PDE10APARP1PARP2PARP14PARP11 | |
| SCHEMBL15538526 | 0.81 | PDE10A (1.00) | PDE10APARP1PARP2PARP14PARP11 | |
| SCHEMBL20355545 | 0.79 | PARP1 (0.71) | PDE10APARP1PARP2PARP14PARP11 | |
| SCHEMBL30111044 | 0.78 | PARP1 (0.83) | PDE10APARP1PARP2 | |
| SCHEMBL16366335 | 0.78 | PARP1 (0.66) | PDE10APARP1PARP2PARP14 | |
| SCHEMBL21072527 | 0.78 | PARP1 (0.69) | PDE10APARP1PARP2PARP14PARP11 | |
| SCHEMBL31483741 | 0.78 | PARP1 (0.69) | PDE10APARP1PARP2PARP14PARP11 | |
| SCHEMBL16366312 | 0.77 | PDE10A (0.54) | PDE10APARP1PARP2PARP14 | |
| SCHEMBL17298080 | 0.76 | PARP1 (0.66) | PDE10APARP1PARP2PARP14PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | claimed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | PDE10A 1223/4885PARP1 2/4885PARP2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.